118650-08-1

Usage

Uses

Used in Organic Synthesis:
3-Pyridineacetic acid, 5-bromo-, Methyl ester is used as a building block in organic synthesis for the creation of various complex organic molecules. Its unique structure allows for further chemical reactions and modifications, making it a valuable component in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Chemical Research:
In the field of chemical research, 3-Pyridineacetic acid, 5-bromo-, Methyl ester is employed as an intermediate for studying the properties and reactions of pyridine and acetic acid derivatives. Its presence in various chemical reactions can provide insights into the reactivity and selectivity of different functional groups, contributing to the advancement of chemical knowledge and the development of new synthetic methods.
Used in Pharmaceutical Industry:
3-Pyridineacetic acid, 5-bromo-, Methyl ester is used as a key intermediate in the synthesis of certain pharmaceutical compounds. Its unique structure and reactivity can be leveraged to create novel drug candidates with potential therapeutic applications, such as in the treatment of various diseases and disorders.
Used in Agrochemical Industry:
In the agrochemical industry, 3-Pyridineacetic acid, 5-bromo-, Methyl ester is utilized as a precursor for the development of new agrochemicals, including pesticides and herbicides. Its chemical properties can be harnessed to create effective and targeted compounds for crop protection and management.
Due to the complex nature of 3-Pyridineacetic acid, 5-bromo-, Methyl ester, it is essential to handle and store 3-Pyridineacetic acid, 5-broMo-, Methyl ester with the appropriate safety precautions and in accordance with regulatory guidelines to ensure the safety of both individuals and the environment.

Upstream product

• 39891-12-8 5-bromo-3-pyridineacetic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 67-56-1 methanol 
• 186581-53-3 diazomethane 
• 54648-79-2 N,N’-diisopropyl-O-methylisourea 
• 74-89-5 methylamine 
• 625-92-3 3,5-dibromopyridine 
• 38330-80-2 monomethyl monopotassium malonate 

Downstream Products

• 597584-53-7 methyl (5-phenylpyridin-3-yl)acetate 
• 936371-69-6 methyl 2-(5-bromopyridin-3-yl)-3-(furan-2-yl)-3-oxopropanoate 
• 597584-55-9 methyl 4-methyl-2-(5-phenylpyridin-3-yl)pentanoate 
• 597584-56-0 4-methyl-2-(5-phenylpyridin-3-yl)pentanoic acid 
• 597584-54-8 methyl 4-methyl-2-(5-phenylpyridin-3-yl)pent-4-enoate 
• 1020658-27-8 (6'-{4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl}-3,3'-bipyridin-5-yl)acetic acid 
• 917026-60-9 [5-(4-{1-[4-(3,3-dimethyl-2-oxo-butoxy)-3-methyl-phenyl]-1-ethyl-propyl}-phenyl)-pyridin-3-yl]-acetic acid methyl ester 
• 917025-49-1 [5-(4-{1-ethyl-1-[3-methyl-4-(4,4,4-trifluoro-3-methoxymethoxy-3-trifluoromethyl-1-butynyl)-phenyl]-propyl}-2-methyl-phenyl)-pyridin-3-yl]-acetic acid methyl ester 
• 917025-41-3 [5-(4-{1-ethyl-1-[3-methyl-4-((E)-4,4,4-trifluoro-3-hydroxy-3-trifluoromethyl-1-butenyl)-phenyl]-propyl}-2-methyl-phenyl)-pyridin-3-yl]-acetic acid methyl ester 
• 917025-52-6 [5-(4-{1-ethyl-1-[4-((E)-3-ethyl-3-hydroxy-1-pentenyl)-3-methyl-phenyl]-propyl}-2-methyl-phenyl)-pyridin-3-yl]-acetic acid methyl ester 
• 917025-88-8 [5-(4-{1-ethyl-1-[4-(3-ethyl-3-hydroxypentyl)-3-methyl-phenyl]-propyl}-2-methyl-phenyl)-pyridin-3-yl]-acetic acid methyl ester 
• 917025-80-0 [5-(4-{1-[4-(3,3-dimethyl-2-oxo-butoxy) - 3-methyl-phenyl]-1-ethyl-propyl}-2-methyl-phenyl)-pyridin-3-yl]-acetic acid methyl ester 
• 917025-77-5 [5-(4-{1-ethyl-1-[4-(2-hydroxy-3,3-dimethyl-butoxy)-3-methyl-phenyl]-propyl}-2-methyl-phenyl)-pyridin-3-yl]-acetic acid methyl ester 
• 917025-65-1 [5-(4-{1-ethyl-1-[3-methyl-4-(1-trimethylsilanyloxy-cyclopentylethynyl)-phenyl]-propyl}-2-methyl-phenyl)-pyridin-3-yl]-acetic acid methyl ester 

Relevant academic research and scientific papers

A Modular Synthesis of Teraryl-Based α-Helix Mimetics, Part 5: A Complete Set of Pyridine Boronic Acid Pinacol Esters Featuring Side Chains of Proteinogenic Amino Acids

Teraryl-based α-helix mimetics have proven to be useful compounds for the inhibition of protein-protein interactions (PPI). We have developed a modular and flexible approach for the synthesis of teraryl-based α-helix mimetics using pyridine containing boronic acid building blocks to increase the water solubility. Following our initial publication in which we have introduced the methodology in combination with sequential Pd-catalyzed cross-coupling for teraryl assembly, we can now report a complete set of pyridine based boronic acid building blocks decorated with side chains of all proteinogenic amino acids relevant for PPI (Ala, Arg, Asn, Asp, Cys, Gln, Glu, His, Ile, Leu, Lys, Met, Phe, Ser, Thr, Trp, Tyr, Val) to complement the core fragment set. For a representative set of teraryls we have studied the influence of the pyridine rings on the solubility of the assembled oligoarenes.

RORGAMMA MODULATORS AND USES THEREOF

The present invention provides novel compounds that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.

Mild Esterification of Carboxylic Acids via Continuous Flow Diazotization of Amines

A new continuous flow protocol for the diazotization of methylamine with 1,3-propanedinitrite in THF is reported. The synthesis of methyl esters was achieved in high yields from a variety of carboxylic acids in 20 min at 90 °C. Additionally, this protocol was extended to other aryl and alkyl amines, namely secondary amines, to produce various substituted esters in high yield using 2-MeTHF as a solvent. The reaction conditions were compatible with many functional groups, namely nitrogen-containing heterocycles, alkynes, alkenes, alcohols, and phenols. Mechanistic investigations reveal that the reaction appears to proceed through a transient diazonium species rather than a diazo intermediate.

BIARYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS

The present invention relates to compounds of the formula (I), wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease ca

NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4? R5, R6, A1, A2, A3, A4, A5 and n are as described herein,compositions including the compounds and methods of using the compounds as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrom.

NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, A1, A2, A3, A4, A5 and n are as

ALDOSTERONE SYNTHASE INHIBITORS

This invention relates to tricyclic triazole analogues of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.

Substituted piperidines

The invention relates to novel substituted piperidines, to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders and tumour disorders.

ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS

The present invention provides a compound of Formula (I); a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Azacycloalkane derivatives of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.